Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus R-CHOEP-14 in younger high-risk diffuse large B-cell lymphoma
2017-003256-22Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Universitätsklinikum Münster. Started Nov 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2017-003256-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003256-22.